Expression of Allograft Inflammatory Factor-1 (AIF-1) in Hepatocellular Carcinoma

Zhang, Qifan; Sun, Shibo; Zhu, Chen; Xie, Fang; Cai, Qing; Sun, Hang; Chen, Gang; Liang, Xiangdang; Xie, Haorong; Shi, Jie; Liao, Yan; Zhou, Jie

doi:10.12659/msm.908510

Cited by 7 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that the AIF-1 expression level in NSCLC tissue was positively associated with malignant characteristics such as lymph node metastasis, and TNM stage. This finding is in line with previous data obtained for hepatocellular carcinoma [ 34 ]. Furthermore, lymph node involvement was associated with an elevated serum level of AIF-1 in patients with cervical cancer [ 35 ], supporting the proposal that AIF-1 may be a marker of more aggressive tumor behavior.…”

Section: Discussionsupporting

confidence: 94%

AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Allogeneic inflammatory factor-1 (AIF-1) overexpression has been reported to be associated with tumorigenesis and tumor metastasis. This study aimed to investigate the role of AIF-1 in the development and progression of non-small cell lung cancer (NSCLC). AIF-1, IL-6, and VEGF expressions in human NSCLC tissue were examined by immunofluorescence staining. Bioinformatics analyses were performed to identify AIF-1-related molecules and pathways in NSCLC. Human lung cancer A549 cell proliferation was assessed by CCK-8 assay, and cell migration was evaluated with wound-healing assay. IL-6 and VEGF secretions in A549 cell culture supernatants were quantified using the Elecsys IL-6 immunoassay kit and Vascular Endothelial Growth Factor Assay Kit. RT-PCR and western blot were performed to quantify the expressions of AIF-1, IL-6, and VEGF mRNAs and proteins involved in p38-MAPK and JAK/STAT3 signaling such as p-p38 and p-STAT3. The effects of AIF-1 on A549 cell proliferation and the expressions of IL-6 and VEGF were assessed using SB203580 and ruxolitinib. The results showed that AIF-1 expression was higher in human NSCLC tissue than that in paracancer tissue. High AIF-1 expression was associated with metastasis, higher TNM stage, and poorer survival. Bioinformatics connected AIF-1 to JAK/STAT signaling in NSCLC. AIF-1 increased A549 cell proliferation, migration, IL-6 secretion and, VEGF secretion, and these effects were attenuated by inhibition of p38-MAPK or JAK/STAT3 signaling. In conclusion, AIF-1 may promote aggressive NSCLC behavior via activation of p38-MAPK and JAK/STAT signaling.

show abstract

Section: Discussionsupporting

confidence: 94%

AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Whilst not a marker of stemness, MMP9 is linked with EMT as it plays a key role in degradation of the extracellular matrix and therefore by aiding the escape of epithelial tumor cells from their location of origin, MMP9 expression has been linked to the metastatic potential of HCC cells [53]. AIF-1 has been shown to promote proliferation and migration of breast cancer cells [54,55], and whilst its role in HCC remains unknown, increased mRNA levels in HCC tumor cells have been observed [56]. Presence of TA-AAbs to the majority of these antigens in HCC patients have previously been described [15,20,[57][58][59].…”

Section: Plos Onementioning

confidence: 99%

Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) continues to be a leading challenge in modern oncology. Early detection via blood-based screening tests has the potential to cause a stage-shift at diagnosis and improve clinical outcomes. Tumor associated autoantibodies (TA-AAbs) have previously shown the ability to distinguish HCC from patients with high-risk liver disease. This research aimed to further show the utility of TA-AAbs as biomarkers of HCC and assess their use in combination with Alpha-fetoprotein (AFP) for detection of HCC across multiple tumor stages. Methods Levels of circulating G class antibodies to 44 recombinant tumor associated antigens and circulating AFP were measured in the serum of patients with HCC, non-cancerous chronic liver disease (NCCLD) and healthy controls via enzyme-linked immunosorbent assay (ELISA). TA-AAb cutoffs were set at the highest Youden's J statistic at a specificity �95.00%. Panels of TA-AAbs were formed using net reclassification improvement. AFP was assessed at a cutoff of 200 ng/ml. Results Sensitivities ranged from 1.01% to 12.24% at specificities of 95.96% to 100.00% for single TA-AAbs. An ELISA test measuring a panel of 10 of these TA-AAbs achieved a combined sensitivity of 36.73% at a specificity of 89.89% when distinguishing HCC from NCCLD controls. At a cutoff of 200 ng/ml, AFP achieved a sensitivity of 31.63% at a specificity of 100.00% in the same cohort. Combination of the TA-AAb panel with AFP significantly

show abstract

“…This molecule orchestrates both immune (i.e., controlling proliferation, the migration and polarization of T lymphocytes, and the activation of macrophages or microglia or modulating dendritic cells) and non-immune actions (i.e., modulation of membrane ruffling, activation of endothelial cells, cell cycle progression and F-actin binding activity) [44]. The role of AIF-1 in cancer has been demonstrated in past works, mainly focused on hepatocellular carcinoma [45], breast [46], lung [47] and other types of cancer [48][49][50]. To our best knowledge, no studies have been conducted to understand the carcinogenic role and prognostic value of AIF-1 in pancreatic cancer; a recent study [51] revealed that AIF-1 acts as a robust diagnostic and prognostic biomarker in several types of cancer and is closely correlated with tumor immune infiltration.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Histone Acetyl Transferase 1 (HAT-1) and Inflammatory Signatures in Pancreatic Cancer

Ortega,

Jiménez-Álvarez,

Fraile-Martinez

et al. 2024

CIMB

View full text Add to dashboard Cite

Pancreatic cancer is a type of gastrointestinal tumor with a growing incidence and mortality worldwide. Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of cases, and late-stage diagnosis is common, leading to a 5-year survival rate of less than 10% in high-income countries. The use of biomarkers has different proven translational applications, facilitating early diagnosis, accurate prognosis and identification of potential therapeutic targets. Several studies have shown a correlation between the tissue expression levels of various molecules, measured through immunohistochemistry (IHC), and survival rates in PDAC. Following the hallmarks of cancer, epigenetic and metabolic reprogramming, together with immune evasion and tumor-promoted inflammation, plays a critical role in cancer initiation and development. In this study, we aim to explore via IHC and Kaplan–Meier analyses the prognostic value of various epigenetic-related markers (histones 3 and 4 (H3/H4), histone acetyl transferase 1 (HAT-1), Anti-Silencing Function 1 protein (ASF1), Nuclear Autoantigenic Sperm Protein (NASP), Retinol Binding Protein 7 (RBBP7), importin 4 (IPO4) and IPO5), metabolic regulators (Phosphoglycerate mutase (PGAM)) and inflammatory mediators (allograft inflammatory factor 1 (AIF-1), interleukin 10 (IL-10), IL-12A and IL-18) in patients with PDAC. Also, through a correlation analysis, we have explored the possible interconnections in the expression levels of these molecules. Our results show that higher expression levels of these molecules are directly associated with poorer survival rates in PDAC patients, except in the case of IL-10, which shows an inverse association with mortality. HAT1 was the molecule more clearly associated with mortality, with a hazard risk of 21.74. The correlogram demonstrates an important correlation between almost all molecules studied (except in the case of IL-18), highlighting potential interactions between these molecules. Overall, our study demonstrates the relevance of including different markers from IHC techniques in order to identify unexplored molecules to develop more accurate prognosis methods and possible targeted therapies. Additionally, our correlation analysis reveals potential interactions among these markers, offering insights into PDAC’s pathogenesis and paving the way for targeted therapies tailored to individual patient profiles. Future studies should be conducted to confirm the prognostic value of these components in PDAC in a broader sample size, as well as to evaluate the possible biological networks connecting them.

show abstract

Expression of Allograft Inflammatory Factor-1 (AIF-1) in Hepatocellular Carcinoma

Cited by 7 publications

References 34 publications

AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer

AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer

Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma

Prognostic Value of Histone Acetyl Transferase 1 (HAT-1) and Inflammatory Signatures in Pancreatic Cancer

Contact Info

Product

Resources

About